Overview
Zentalis Q3 operating expenses decreased to $33.7 mln from $51.4 mln last year
Net loss for Q3 2025 was $26.7 mln, an improvement from $40.2 mln last year
Company has $280.7 mln in cash, supporting operations into late 2027
Outlook
Company's cash supports operations into late 2027
Result Drivers
COST REDUCTION - Decrease in R&D expenses contributed to lower operating expenses for the quarter
STRONG CASH POSITION - Company has $280.7 mln in cash, supporting operations into late 2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.37 | ||
Q3 Net Income | -$26.69 mln | ||
Q3 Operating Expenses | $33.73 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 76.7% above its November 7 closing price of $1.28
Press Release: ID:nGNX24RF7F
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)